Clinical Trials Browser

Neoplasm, Residual × selinexor × Clear all

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2 Withdrawn

Multiple Myeloma, Neoplasm, Residual